N/A N=15 The Effect of Rituximab on the Development of Anti-Donor Antibodies
Renal Transplant Rejection
Primary: Change in Biopsy Cell Densities From Baseline to Follow-up — -164; -122.5; -129.4; 30.4 cells/mm^3 — p=0.25
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia
Primary: Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism — 60; 30; 33.3 percentage of participants
Phase 3 N=36 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Phase 2 N=40 Belatacept Post Depletional Repopulation to Facilitate Tolerance
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 4 N=167 Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes
Phase 2 N=74 Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Acute Graft Versus Host Disease
Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants
Phase 3 N=236 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Phase 2 N=21 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Phase 2 N=48 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Incidence of Acute Graft-versus-host Disease (GVHD) — 44.7 percentage of participants
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
Phase 2 N=32 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Infection
Primary: Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100 — 37.3 Percentage of patients developing aGVHD
Phase 2 N=5 Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
Graft Rejection · Kidney Disease
Primary: Number of Patients With Renal Allograft Rejection — 5 participant
Phase 2 N=10 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Kidney Transplantation · Kidney Disease
Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events
Phase 2 N=46 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Phase 1 N=20 Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
Phase 3 N=223 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
Chronic Obstructive Pulmonary · Idiopathic Pulmonary Fibrosis · Cystic Fibrosis
Primary: Number of Participants With the Event Death, Graft Loss, Acute Rejection and/or Loss to Follow-up (Whichever Occurred First) — 33; 29; 30 participants
Phase 2 N=35 Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Leukemia · Lymphoma · Myelodysplastic Syndrome
Primary: The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion — 32 Percentage of participants
Phase 2 N=33 Tocilizumab for Renal Graft Inflammation
Late Complication From Kidney Transplant
Primary: Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months — 3; 10 Participants — p=0.033
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 1 N=2 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Phase 3 N=174 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Number of Patients With Grades II-IV Acute GVHD — 39; 22; 3 Participants
Phase 2 N=150 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Incidence of Grade III/IV GVHD — 2; 4 Participants
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=180 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Phase 3 N=28 Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection
Kidney Diseases
Primary: Stimulation of Growth After 12 Months (Delta Z-score) — 1.2; 0.6 units on a scale
Phase 2 N=2 Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants
Phase 2 N=30 Randomized Trial for Mixed Acute Rejection
Graft Rejection
Primary: Number of Patients in Each Group With Any of the Following: Rejection Reversal or Recurrent Rejection — 0; 0; 0; 2 participants
Phase 1 N=9 Detection of Graft Versus Host Disease With [18F]F-AraG
Graft Versus Host Disease
Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants